EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODY molecule

Annemie Deiteren, Emmanuel Krupka, Lieselot Bontinck, Karine Imberdis, Griet Conickx, Selcuk Bas, Naimish Patel, Heribert W Staudinger, Benjamin T Suratt

European Respiratory Journal · 2025-04 · 65 (4) · 2401461

DOI: 10.1183/13993003.01461-2024 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift European Respiratory Journal, online erschienen am 30.01.2025. Verfasst von Annemie Deiteren und 8 weiteren Autor:innen. Beteiligte Einrichtung: Sanofi, Ghent, Belgium annemie.deiteren@sanofi.com. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Asthma, Single-Domain Antibodies. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Monovalent biologics blocking thymic stromal lymphopoietin (TSLP) or interleukin (IL)-13 have been shown to elicit pharmacodynamic responses in asthma following a single dose. Therefore, dual blockade of these cytokines may result in an enhanced response compared to single targeting and has the potential to break efficacy ceilings in asthma. This study assessed the safety and tolerability of lunsekimig, a bispecific NANOBODY molecule that blocks TSLP and IL-13, and its effect on type 2 (T2) inflammatory biomarkers and lung function in asthma.

Methods

This was a phase 1b, single-dose (subcutaneous lunsekimig 400 mg or placebo), randomised (2:1), double-blind, proof-of-mechanism study in 36 participants with mild-to-moderate asthma and elevated exhaled nitric oxide fraction ( F ENO ; ≥25 ppb), a marker of airway inflammation. The primary end-point was safety and tolerability through day 71. The main pharmacodynamic secondary end-point was change from baseline in F ENO at day 29.

Results

Lunsekimig was well tolerated, with no serious treatment-emergent adverse events. F ENO was significantly reduced from day 8 through day 29 after a single dose, with change from baseline of −40.9 (90% CI −55.43– −26.39) ppb (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificAsthmaSingle-Domain AntibodiesAdultAgedFemaleHumansMaleMiddle AgedYoung AdultBiomarkersCytokinesDouble-Blind MethodInterleukin-13Nitric OxideProof of Concept StudyThymic Stromal LymphopoietinTreatment Outcome

Substanzen

Antibodies, BispecificBiomarkersCytokinesInterleukin-13Nitric OxideSingle-Domain AntibodiesThymic Stromal Lymphopoietin

Autor:innen und Institutionen

  • Sanofi, Ghent, Belgium annemie.deiteren@sanofi.com.
  • Sanofi, Montpellier, France.
  • Sanofi, Ghent, Belgium.
  • Charité Research Organisation, Berlin, Germany.
  • CRISPR Therapeutics, Boston, MA, USA.
  • Sanofi, Bridgewater, NJ, USA.

Förderung

  • Sanofi

Zitieren

APA

Deiteren, A., Krupka, E., Bontinck, L., Imberdis, K., Conickx, G., Bas, S., Patel, N., Staudinger, H. W., & Suratt, B. T. (2025). A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODY molecule. European Respiratory Journal, 65(4), 2401461. https://doi.org/10.1183/13993003.01461-2024

Vancouver

Deiteren A, Krupka E, Bontinck L, Imberdis K, Conickx G, Bas S, et al. A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODY molecule. European Respiratory Journal. 2025;65(4):2401461. doi:10.1183/13993003.01461-2024

BibTeX
@article{Deiteren2025,
  author = {Deiteren, Annemie and Krupka, Emmanuel and Bontinck, Lieselot and Imberdis, Karine and Conickx, Griet and Bas, Selcuk and Patel, Naimish and Staudinger, Heribert W and Suratt, Benjamin T},
  title = {A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODY molecule},
  journal = {European Respiratory Journal},
  year = {2025},
  volume = {65},
  number = {4},
  pages = {2401461},
  doi = {10.1183/13993003.01461-2024}
}
Kostenlos starten →